Combination of Mesenchymal Stem Cells-delivered Oncolytic Virus and Prodrug Activation Increases Efficacy and Safety in Cancer Therapy
碩士 === 國立陽明大學 === 臨床醫學研究所 === 102 === Oncolytic viruses, such as conditionally replicative adenoviruses (CRAds), have been successfully approved in clinical trials for cancer therapy. However the anti-tumor efficacy was still not ideal. Gene-directed enzyme-prodrug therapy (GDEPT), that is prodrug a...
Main Authors: | Mei-Hsuan Wu, 吳美萱 |
---|---|
Other Authors: | Shih-Chieh Hung |
Format: | Others |
Language: | en_US |
Published: |
2014
|
Online Access: | http://ndltd.ncl.edu.tw/handle/56722525246889477551 |
Similar Items
-
Combination of Mesenchymal Stem Cell-Delivered Oncolytic Virus with Prodrug Activation Increases Efficacy and Safety of Colorectal Cancer Therapy
by: Chun-Te Ho, et al.
Published: (2021-05-01) -
Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs
by: Kazue Kasai, et al.
Published: (2013-01-01) -
Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment
by: Mohsen Keshavarz, et al.
Published: (2020-05-01) -
Correction to: Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment
by: Mohsen Keshavarz, et al.
Published: (2020-11-01) -
Mesenchymal stem cells and oncolytic viruses: joining forces against cancer
by: Rafael Moreno
Published: (2021-02-01)